1.Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression.
Eun Hye SEO ; Ji Hyeon NAMGUNG ; Chung Sik OH ; Seong Hyop KIM ; Seung Hyun LEE
Immune Network 2018;18(3):e23-
Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells that show increased expression in cancer patients; however, the molecular mechanisms underlying their generation and function are unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer (BC), the presence and relevance of monocytic (Mo)-MDSCs are unknown. Here, we report for the first time increased chemokine and chemokine receptor production by Mo-MDSCs in BC patients. A clear population of Mo-MDSCs with the typical cell surface phenotype (human leukocyte antigen-antigen D related [HLA-DR]low/− CD11b+ CD33+ CD14+) increased significantly during disease progression. In addition, the chemokine receptor expression level on Mo-MDSCs in patients with invasive BC was the highest. Furthermore, different chemokine receptor expression patterns were noted in Mo-MDSCs between healthy controls (HC) and BC patients. Additionally, CD4 T cells proliferations were significantly decreased in the invasive BC groups compared with the HC group. However, the ductal carcinoma in situ (DCIS) group had no significantly compared with the HC group. Our data suggest that monitoring chemokine and chemokine receptor production by Mo-MDSCs may represent a novel and simple biomarker for assessing disease progression in BC patients.
Breast Neoplasms
;
Carcinoma, Intraductal, Noninfiltrating
;
Chemokines*
;
Disease Progression
;
Humans
;
Leukocytes
;
Myeloid Cells
;
Phenotype
;
Receptors, Chemokine
;
T-Lymphocytes
2.Diagnostic value of peripheral blood immune profiling in colorectal cancer.
Joungbum CHOI ; Hyung Gun MAENG ; Su Jin LEE ; Young Joo KIM ; Da Woon KIM ; Ha Na LEE ; Ji Hyeon NAMGUNG ; Hyun Mee OH ; Tae Joo KIM ; Ji Eun JEONG ; Sang Jean PARK ; Yong Man CHOI ; Yong Won KANG ; Seo Gue YOON ; Jong Kyun LEE
Annals of Surgical Treatment and Research 2018;94(6):312-321
PURPOSE: Little is known about the clinical value of peripheral blood immune profiling. Here, we aimed to identify colorectal cancer (CRC)-related peripheral blood immune cells and develop liquid biopsy-based immune profiling models for CRC diagnosis. METHODS: Peripheral blood from 131 preoperative patients with CRC and 174 healthy controls was analyzed by flow cytometry and automated hematology. CRC-related immune factors were identified by comparing the mean values of immune cell percentages and counts. Subsequently, CRC diagnostic algorithms were constructed using binary logistic regression. RESULTS: Significant differences were observed in percentages and counts of white blood cells, lymphocytes, neutrophils, regulatory T cells, and myeloid-derived suppressor cells (MDSCs) of patients and controls. The neutrophil/lymphocyte and Th1/Th2 ratios were also significantly different. Likewise, the percentages and counts of peripheral blood programed death 1, cytotoxic T lymphocyte antigen 4, B-and T-lymphocyte attenuator, and lymphocyte activation gene-3 were higher in patients with CRC. The binary logistic regression model included 12 variables, age, CD3+%, NK%, CD4+CD279+%, CD4+CD25+%, CD4+CD152+%, CD3+CD366+%, CD3+CD272+%, CD3+CD223+%, CD158b−CD314+CD3−CD56+%, Th2%, and MDSCs cells/µL, for the prediction of cancer. Results of retrospective and prospective evaluation of the area under the curve, sensitivity, and specificity were 0.980 and 0.940, 91.53% and 85.80%, and 93.50% and 86.20%, respectively. CONCLUSION: Peripheral blood immune profiling may be valuable in evaluating the immunity of CRC patients. Our liquid biopsy-based immune diagnostic method and its algorithms may serve as a novel tool for CRC diagnosis. Future largescale studies are needed for better characterization of its diagnostic value and potential for clinical application.
Blood Cells
;
Colorectal Neoplasms*
;
CTLA-4 Antigen
;
Diagnosis
;
Early Detection of Cancer
;
Flow Cytometry
;
Hematology
;
Humans
;
Immunologic Factors
;
Leukocytes
;
Logistic Models
;
Lymphocyte Activation
;
Lymphocytes
;
Methods
;
Neutrophils
;
Prospective Studies
;
Retrospective Studies
;
Sensitivity and Specificity
;
T-Lymphocytes
;
T-Lymphocytes, Regulatory
3.Erratum to: Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients.
Ji Yong JANG ; Sang Hak LEE ; Byung Soo KIM ; Hong Seog SEO ; Woo Shik KIM ; Youngkeun AHN ; Nae Hee LEE ; Kwang Kon KOH ; Tae Soo KANG ; Sang Ho JO ; Bum Kee HONG ; Jang Ho BAE ; Hyoung Mo YANG ; Kwang Soo CHA ; Bum Soo KIM ; Choong Hwan KWAK ; Deok Kyu CHO ; Ung KIM ; Joo Hee ZO ; Duk Hyun KANG ; Wook Bum PYUN ; Kook Jin CHUN ; June NAMGUNG ; Tae Joon CHA ; Jae Hyeon JUHN ; YeiLi JUNG ; Yangsoo JANG
Korean Circulation Journal 2015;45(4):349-349
In this article, on page 230, Fig. 2A needs to be corrected.
4.Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients.
Ji Yong JANG ; Sang Hak LEE ; Byung Soo KIM ; Hong Seog SEO ; Woo Shik KIM ; Youngkeun AHN ; Nae Hee LEE ; Kwang Kon KOH ; Tae Soo KANG ; Sang Ho JO ; Bum Kee HONG ; Jang Ho BAE ; Hyoung Mo YANG ; Kwang Soo CHA ; Bum Soo KIM ; Choong Hwan KWAK ; Deok Kyu CHO ; Ung KIM ; Joo Hee ZO ; Duk Hyun KANG ; Wook Bum PYUN ; Kook Jin CHUN ; June NAMGUNG ; Tae Joon CHA ; Jae Hyeon JUHN ; Yeili JUNG ; Yangsoo JANG
Korean Circulation Journal 2015;45(3):225-233
BACKGROUND AND OBJECTIVES: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS: Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. RESULTS: A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p<0.001). Changes of sitSBP by LSM were -13.2, -10.8, and -4.9 mm Hg, and was greater in the combination, as compared to rosuvastatin (p=0.006) and not valsartan (p=0.42). Percentage changes of LDL-C by LSM were -52, -4, and -47% in each group, and was greater in the combination, as compared to valsartan (p<0.001), similar to rosuvastatin (p=0.16). Most AEs were mild and resolved by the end of the study. CONCLUSION: Combination treatment with valsartan and rosuvastatin exhibited an additive blood pressure-lowering effect with acceptable tolerability, as compared to valsartan monotherapy. Its lipid lowering effect was similar to rosuvatatin monotherapy.
Blood Pressure
;
Drug Therapy, Combination
;
Humans
;
Least-Squares Analysis
;
Rosuvastatin Calcium
;
Valsartan